| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/21/2011 | US20110177131 siRNA SILENCING OF FILOVIRUS GENE EXPRESSION |
| 07/21/2011 | US20110177110 Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof |
| 07/21/2011 | US20110177108 Lipid compounds for supression of tumorigenesis |
| 07/21/2011 | US20110177107 Predicting and reducing alloimmunogenicity of protein therapeutics |
| 07/21/2011 | US20110177106 Novel Therapeutic Methods for Treating Inflammation and Immune System Disorders |
| 07/21/2011 | US20110177105 Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications |
| 07/21/2011 | US20110177102 Targeted double stranded rna mediated cell killing |
| 07/21/2011 | US20110177100 Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy |
| 07/21/2011 | US20110177099 Genetic variations associated with drug resistance |
| 07/21/2011 | US20110177098 Tm4sf4 and modulators thereof and methods for their use |
| 07/21/2011 | US20110177097 Methods for modulating expression of creb |
| 07/21/2011 | US20110177096 Use of gpr151 modulators for the treatment of pain |
| 07/21/2011 | US20110177089 Apoptosis inducer |
| 07/21/2011 | US20110177085 Bitter Taste Receptors |
| 07/21/2011 | US20110177084 Novel use application of sugar chain-recognizing receptor |
| 07/21/2011 | US20110177082 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 07/21/2011 | US20110177065 Methods of treating/preventing inflammation using combination of il-1 antagonist and il-18 binding protein |
| 07/21/2011 | US20110177061 Methods of treating and preventing neurological disorders using docosahexaenoic acid |
| 07/21/2011 | US20110177060 Iap bir domain binding compounds |
| 07/21/2011 | US20110177057 Pharmaceutical preparation and manufacturing method thereof |
| 07/21/2011 | US20110177055 Compounds and compositions as channel activating protease inhibitors |
| 07/21/2011 | US20110177054 Use of endo-lysosomal system and secreted vesicles (exosome-like) in treatments and diagnostics based on small rna and experimental study of small rna |
| 07/21/2011 | US20110177046 Dithiazolidine and thiazolidine derivatives as anticancer agents |
| 07/21/2011 | US20110177042 Method for Dedifferentiating Melanocytes |
| 07/21/2011 | US20110177038 Inhibition of Tumor Growth via Peroxiredoxin 3 |
| 07/21/2011 | US20110177035 Use of secretor, lewis and sialyl antigen levels in clinical samples as predictors of risk for disease |
| 07/21/2011 | US20110177033 Ras responsive element binding protein 1 (rreb1) as a therapeutic target for thalassemias and sickle cell anemia |
| 07/21/2011 | US20110177031 Eicosapentaenoic Acid-Producing Microorganisms, Fatty Acid Compositions, and Methods of Making and Uses Thereof |
| 07/21/2011 | US20110177030 Hepatitis C Inhibitor Compounds |
| 07/21/2011 | US20110177028 Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly |
| 07/21/2011 | US20110177026 Use of Alpha-Glucosidase Inhibitors to Treat Alphavirus Infections |
| 07/21/2011 | US20110177022 Mammalian Cytokines; Related Reagents and Methods |
| 07/21/2011 | US20110177021 Composition for forming a temporary obstruction and method of forming the same |
| 07/21/2011 | US20110177011 Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton's tyrosine kinase by such compounds |
| 07/21/2011 | US20110177005 Stable nanoemulsions for ultrasound-mediated drug delivery and imaging |
| 07/21/2011 | US20110177002 Cylic polyamines for binding phosphatidylserine |
| 07/21/2011 | US20110177001 Screening assay employing dex and gdf8 |
| 07/21/2011 | US20110177000 Use of S-Nitrosothiol Signaling to Treat Disordered Control of Breathing |
| 07/21/2011 | US20110176997 Method to make porous materials and their applications |
| 07/21/2011 | US20110176994 Buoyant Polymer Particles for Delivery of Therapeutic Agents to the Central Nervous System |
| 07/21/2011 | US20110173928 Process to improve stability of a pharmaceutical composition |
| 07/21/2011 | DE102010004986A1 New bromocriptine is prolactin inhibitor, useful for initiating, without concurrent medication, prolactin increase in male and female depressed patients for normalization of mood, and for treatment of reactive and endogenous depression |
| 07/21/2011 | DE102010004957A1 Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung Biologically active molecules for influencing viral, bacterial, parasite-infected cells and / or tumor cells and methods of use thereof |
| 07/21/2011 | DE102004051554B4 Verfahren zur Herstellung von pigment- und/oder effektstoffhaltigen Minen A process for the production of pigment and / or effect substance-containing mines |
| 07/21/2011 | CA2822220A1 Solid-forming local anesthetic formulations for pain control |
| 07/21/2011 | CA2804128A1 Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring |
| 07/21/2011 | CA2799474A1 Carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring |
| 07/21/2011 | CA2792134A1 Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring |
| 07/21/2011 | CA2791445A1 2,5,7-substituted oxazolopyrimidine derivatives |
| 07/21/2011 | CA2790933A1 Stable dosage forms of levomilnacipran |
| 07/21/2011 | CA2787529A1 Treatment of chlamydiaceae infections by means of beta-lactams |
| 07/21/2011 | CA2787236A1 Pharmaceutical use of multicyclic compounds as anti-aids agents |
| 07/21/2011 | CA2787121A1 New anti-malarial agents |
| 07/21/2011 | CA2787115A1 Flurane complex |
| 07/21/2011 | CA2787025A1 Voltage-gated sodium channel blockers |
| 07/21/2011 | CA2787018A1 Compounds and methods |
| 07/21/2011 | CA2786957A1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 |
| 07/21/2011 | CA2786956A1 Compounds for the treatment of autism |
| 07/21/2011 | CA2786819A1 Method for titrating clozapine |
| 07/21/2011 | CA2786800A1 Thiazole and oxazole kinase inhibitors |
| 07/21/2011 | CA2786764A1 Compositions comprising amino acids for prevention and/or treatment of renal disorders |
| 07/21/2011 | CA2786758A1 Methods and compositions for treating bleeding disorders |
| 07/21/2011 | CA2786671A1 Formulations of nano-carriers and methods of preparing the same |
| 07/21/2011 | CA2786649A1 Prophylactic or ameliorating agent for pigmentation |
| 07/21/2011 | CA2786618A1 Lyophilized cake formulations |
| 07/21/2011 | CA2786537A1 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases |
| 07/21/2011 | CA2786465A1 Certain chemical entities, compositions, and methods |
| 07/21/2011 | CA2786443A1 Use of an adrenal hormone-modifying agent |
| 07/21/2011 | CA2786330A1 A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
| 07/21/2011 | CA2786329A1 Anti - infective pyrido (1,2-a) pyrimidines |
| 07/21/2011 | CA2785970A1 Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability |
| 07/21/2011 | CA2785567A1 Inhibitors of flaviviridae viruses |
| 07/21/2011 | CA2785563A1 Inhibitors of flaviviridae viruses |
| 07/21/2011 | CA2785501A1 3-keto-n-propargyl-1-aminoindan |
| 07/21/2011 | CA2785499A1 Isoindolinone inhibitors of phosphatidylinositol 3-kinase |
| 07/21/2011 | CA2785488A1 Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| 07/21/2011 | CA2785455A1 Tricyclic derivatives and their pharmaceutical use and compositions |
| 07/21/2011 | CA2785262A1 Nutritional compositions and methods for optimizing dietary acid-base potential |
| 07/21/2011 | CA2785058A1 Tricyclic derivatives and their pharmaceutical use and compositions |
| 07/21/2011 | CA2785056A1 Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
| 07/21/2011 | CA2784895A1 Paxillin stimulating compositions and cosmetic uses thereof |
| 07/21/2011 | CA2784769A1 Novel substituted triazole derivatives as gamma secretase modulators |
| 07/21/2011 | CA2784765A1 Novel substituted bicyclic triazole derivatives as gamma secretase modulators |
| 07/21/2011 | CA2784565A1 2,5-substituted oxazolopyrimidine derivatives |
| 07/21/2011 | CA2784560A1 Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring |
| 07/21/2011 | CA2784007A1 Pyrrolidine derivatives |
| 07/21/2011 | CA2781578A1 Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| 07/20/2011 | EP2345742A1 RNA sequence-specific mediators of RNA interference |
| 07/20/2011 | EP2345735A1 Xanthomonas campestris with multiple copies of gumB and gumC |
| 07/20/2011 | EP2345728A1 Yeast membrane protein expression system and its application in drug screening |
| 07/20/2011 | EP2345720A2 In vivo production of small interfering RNAs that mediate gene silencing |
| 07/20/2011 | EP2345673A1 Humanized anti-granulocyte MN-3 antibody and uses thereof |
| 07/20/2011 | EP2345665A2 Flavivirus NS1 subunit vaccine |
| 07/20/2011 | EP2345661A1 Modified fluorinated nucleoside analogues |
| 07/20/2011 | EP2345660A1 Anti-xdr-tb agent, anti-mdr-tb agent, and combined anti-tuberculous agent |
| 07/20/2011 | EP2345659A1 Modified fluorinated nucleoside analogues |
| 07/20/2011 | EP2345658A1 Modified fluorinated nucleoside analogues |
| 07/20/2011 | EP2345657A1 Modified fluorinated nucleoside analogues |
| 07/20/2011 | EP2345656A1 Helicobacter pylori bacterium proliferation inhibitor |
| 07/20/2011 | EP2345654A1 Eszopiclone particles and a process for their preparation |